Verify any claim · lenz.io
Claim analyzed
Health“Hormonal contraception, including birth control pills and hormonal IUDs, increases the risk of idiopathic intracranial hypertension.”
The conclusion
The best available evidence does not support this claim. A comprehensive meta-analysis published in Neurology in March 2026, along with earlier population-based case-control and large cohort studies, found no significant association between hormonal contraception — including birth control pills and hormonal IUDs — and idiopathic intracranial hypertension. Clinical guidance from neuro-ophthalmology specialists explicitly states there is no convincing causal evidence. The signals cited in support come from weaker study designs or apply only to specific products, not the class as a whole.
Based on 18 sources: 8 supporting, 6 refuting, 4 neutral.
Caveats
- A 2026 meta-analysis in Neurology and multiple controlled epidemiological studies found no association between hormonal contraception and IIH, directly contradicting the claim.
- Supporting evidence relies on FAERS disproportionality data and small descriptive studies — methodologically weaker designs that cannot establish causation for a drug class.
- The claim conflates product-specific safety signals (e.g., for etonogestrel ring or medroxyprogesterone) with a broad class-wide risk that the controlled evidence does not support.
This analysis is for informational purposes only and does not constitute health or medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making health-related decisions.
Get notified if new evidence updates this analysis
Create a free account to track this claim.
Sources
Sources used in the analysis
Patients with idiopathic intracranial hypertension (IIH) have reported being told to discontinue their hormonal contraceptive, despite a lack of evidence in the literature. Ophthalmologists and neuro-ophthalmologists can help further benefit their patients by providing proactive education illustrating the lack of convincing evidence establishing a causal relationship between hormonal contraceptives and idiopathic intracranial hypertension.
This study found an elevated risk for PTCS among users of etonogestrel vaginal ring and medroxyprogesterone suspension when compared with oral levonorgestrel.
This study provides further evidence against the association between hormonal contraceptive use and the development of IIH. OCP and other hormonal contraceptives were not significantly associated with a higher incidence of IIH, arguing against the need for women with IIH to discontinue their use.
We did not observe a significantly increased hazard of idiopathic intracranial hypertension among women in this large, national cohort using LNG-IUD compared to women using copper IUD, or other forms of highly effective contraception after adjusting for potential important confounders.
We found a higher than expected number of reports of ICH with Mirena® in the FAERS database. The reported odds ratios (ORs) for ICH and papilledema with Mirena® were 1.78 (95% confidence interval [CI] 1.41–2.25) and 1.50 (95% CI 1.10–2.05), respectively. Most reports of ICH secondary to progestins have been with levonorgestrel and medroxyprogesterone.
A comprehensive meta-analysis has found no association between hormonal contraception and idiopathic intracranial hypertension (IIH). Hormonal contraception, including birth control pills and intrauterine devices (IUDs), is not associated with an increased prevalence of a brain pressure disorder called idiopathic intracranial hypertension, according to a meta-analysis published on March 25, 2026, in Neurology.
Doctors do not fully understand the cause of IIH. However, they suspect hormones play a role since this condition is more common in young, overweight women. Sometimes children and adults who are not overweight have IIH. These cases may be related to infection, or to using antibiotics, steroids or high doses of vitamin A.
Hormonal contraception, including birth control pills and intrauterine devices (IUDs), is not associated with an increased prevalence of a brain pressure disorder called idiopathic intracranial hypertension, according to a meta-analysis published on March 25, 2026, in Neurology®, the medical journal of the American Academy of Neurology. Researchers found no association between hormonal contraception and the prevalence of idiopathic intracranial hypertension.
Certain medicines can increase the risk of developing this condition. These medicines include: Amiodarone; Birth control pills such as levonorgestrel; Cyclosporine; Cytarabine; Growth hormone; Isotretinoin; Levothyroxine (children); Lithium carbonate; Minocycline; Nitrofurantoin; Phenytoin; Steroids (starting or stopping them); Sulfa antibiotics; Tamoxifen; Tetracycline; Certain medicines that contain Vitamin A, such as cis-retinoic acid (Accutane).
According to the study authors, counseling against the use of oral contraceptives in patients with IIH is not appropriate. The authors stated that, to date, “there is no evidence that convincingly establishes hormonal contraception, of any form, as a causative factor for the development of IIH,” and they cited studies supporting this viewpoint.
Estrogen-containing contraceptives are absolutely contraindicated in women with IIH due to the potential for worsening intracranial hypertension. Combined oral contraceptive pills are not recommended for patients at risk of thromboembolism, which includes women with IIH and papilledema.
Overall HC use does not have a significant effect on incidence of PTCS, however harm associated with progestin-only contraceptives cannot be excluded. One recent descriptive study demonstrated an increase in risk with intrauterine levonorgestrel (IL) and PTCS, showing an increased odds ratio of 7.70 (95% CI: 3.7-16.0) and 3.91 (95% CI: 1.89-8.06).
Progestin-only methods (intrauterine devices, subdermal implants, or progestin-only pills) and copper IUDs are the safest contraceptive options for women with idiopathic intracranial hypertension, while estrogen-containing contraceptives should be avoided due to potential worsening of intracranial pressure. One retrospective study found a reporting odds ratio of 1.78 for intracranial hypertension with the Mirena® levonorgestrel IUD in the FDA adverse events database.
Estrogen, a common hormone in many birth control pills, has been linked to an increased risk of blood clots and is contraindicated in women with a history of blood clots or congenital thrombophilia. Cerebral blood clots (cerebral venous thrombosis) are a known cause of secondary IH. One form of hormonal birth control, levonorgestrel (Norplant), has been identified as a cause of secondary IH.
One form of hormonal birth control, levonorgestrel (Norplant), has been identified as a cause of secondary IH. Estrogen, a common hormone in many birth control pills, has been linked to an increased risk of blood clots, which are a known cause of secondary IH.
Weakly associated medications include cyclosporine, progestin-only contraceptives, combined oral contraceptives, fluoroquinolones, and others. Pregnancy or hormonal changes may contribute to disease onset or recurrence.
Research has established a potential connection between the use of hormonal birth control products like Mirena IUD, Yaz, and Yasmin, to an increased risk of a severe neurological disorder known as idiopathic intracranial hypertension. A study published in the New England Journal of Medicine in 1995 found a link between IIH and the use of birth control products containing the hormone levonorgestrel.
Pseudotumor cerebri (PTC), also known as idiopathic intracranial hypertension (IIH), has been linked to the use of hormone-containing birth control pills or products. In 1995, the New England Journal of Medicine published a study linking PTC with birth control pills and contraceptive implants containing the hormone levonorgestrel, and officials from the National Institute of Health (NIH) warn that birth control pills are a risk factor for pseudotumor cerebri.
What do you think of the claim?
Your challenge will appear immediately.
Challenge submitted!
Expert review
How each expert evaluated the evidence and arguments
Expert 1 — The Logic Examiner
The claim asserts that hormonal contraception broadly — including birth control pills AND hormonal IUDs — increases IIH risk. Tracing the logical chain: the supporting evidence (Sources 2, 5, 12) shows elevated signals only for specific agents (etonogestrel ring, medroxyprogesterone, Mirena® in FAERS disproportionality analysis), not for hormonal contraception as a class; meanwhile, the higher-quality controlled studies (Sources 3, 4) find no significant association for oral contraceptives or levonorgestrel IUDs after adjustment, and the most recent meta-analysis (Sources 6, 8 — published March 25, 2026 in Neurology) explicitly finds no association between hormonal contraception and IIH prevalence, directly refuting the broad causal claim. The proponent's argument commits a hasty generalization by inferring a class-wide risk from product-specific signals, and an appeal to authority by leaning on MedlinePlus listing levonorgestrel as a risk factor without acknowledging that the controlled epidemiological literature and a 2026 meta-analysis contradict that listing; the opponent correctly identifies that FAERS disproportionality (Source 5) is not incidence data and is highly confounded, and that Source 12 itself qualifies that overall hormonal contraception use does not significantly affect PTCS incidence — meaning the evidence does not logically support the broad causal claim as stated, rendering it false as a general assertion about hormonal contraception as a class.
Expert 2 — The Context Analyst
The claim presents a broad, unqualified causal assertion — that hormonal contraception (including pills and hormonal IUDs) increases IIH risk — but critically omits the most current and highest-quality evidence: a comprehensive meta-analysis published March 25, 2026 in Neurology (Sources 6, 8) found no association between hormonal contraception and IIH prevalence, corroborating earlier population-based case-control and cohort studies (Sources 3, 4) that also found no significant association after adjustment for confounders; the claim also omits that the supporting signals (Sources 2, 5, 12) are either product-specific, methodologically weaker (FAERS disproportionality, single descriptive studies), or explicitly qualified as inconclusive, while clinical guidance (Sources 1, 10) explicitly states there is no convincing causal evidence and that advising patients to discontinue hormonal contraception is not appropriate. Once the full picture is considered — especially the 2026 meta-analysis and the weight of controlled epidemiological evidence — the claim's broad assertion that hormonal contraception increases IIH risk is not supported and creates a misleading impression of established causal risk where the scientific consensus points to no significant association.
Expert 3 — The Source Auditor
The highest-reliability, most directly on-point evidence is the large epidemiologic studies and recent specialty guidance: the population-based case-control study (Source 3, PMC) and the large national cohort on LNG-IUDs (Source 4, PMC) both find no significant increased risk/hazard, and recent neuro-ophthalmology/AAO counseling pieces (Sources 1 and 10) emphasize there is no convincing causal evidence to link hormonal contraception to IIH. The main supporting items are either older and methodologically weaker (FAERS disproportionality signal in Source 5), limited to specific products rather than the class (Source 2), or non-independent/low-quality (Dr.Oracle and advocacy/legal sites), so the best independent evidence overall does not support the broad claim that hormonal contraception (including pills and hormonal IUDs) increases IIH risk.
Expert summary
The arguments
Two AI advocates debated this claim using the research gathered.
Argument for
Multiple peer-reviewed sources directly support the claim that hormonal contraception increases IIH risk: Source 2 found an elevated risk for pseudotumor cerebri syndrome among users of specific hormonal contraceptives, Source 5 identified a statistically significant reporting odds ratio of 1.78 for intracranial hypertension with the levonorgestrel IUD (Mirena®) in the FDA adverse events database, and Source 12 documented an alarming odds ratio of 7.70 for intrauterine levonorgestrel and PTCS in one descriptive study. Furthermore, authoritative medical references including Source 9 (MedlinePlus Medical Encyclopedia) explicitly list birth control pills such as levonorgestrel among medicines that increase the risk of IIH, and Source 14 (Intracranial Hypertension Research Foundation) identifies levonorgestrel as a confirmed cause of secondary IH — collectively demonstrating that the association between hormonal contraception and elevated IIH risk is recognized across clinical literature and established medical encyclopedias.
You're conflating weak, product-specific signals with the motion's broad causal claim: Source 5 is FAERS disproportionality (not incidence and highly confounded), Source 12 itself says overall hormonal contraception isn't significantly associated and only says harm “cannot be excluded,” and Source 2 reports elevated risk only for particular non-IUD methods rather than “hormonal contraception” as a class. More importantly, you ignore the higher-quality epidemiology that directly tests the claim and finds no significant association for oral contraceptives/other hormonal methods (Source 3) and no increased hazard for levonorgestrel IUDs after adjustment (Source 4), while the counseling literature explicitly notes a lack of convincing causal evidence (Source 1; Source 10), making your appeal to MedlinePlus/IHRF (Sources 9, 14) an argument from authority that doesn't outweigh the better-controlled studies.
Argument against
The motion claims hormonal contraception (including pills and hormonal IUDs) increases IIH risk, but large epidemiologic evidence directly contradicts that: a population-based case-control study found no significant association for oral contraceptives or other hormonal methods (Source 3, “A Population-Based, Case-Control Evaluation…”), and a large national cohort found no increased hazard for levonorgestrel IUDs versus copper IUDs after adjustment (Source 4, “Levonorgestrel intrauterine device use…”). More recent clinical and synthesis-level commentary reinforces that there is no convincing causal evidence and that stopping hormonal contraception is not supported (Source 1, “Contraceptive Counseling…”; Source 10, AAO EyeNet), while the main “supporting” items rely on signals limited to specific products or weaker designs (e.g., FAERS disproportionality in Source 5 and elevated risk for certain non-IUD methods in Source 2) that do not establish a general increased risk across hormonal contraception as claimed.
Your reliance on Source 3 and Source 4 to dismiss the entire claim commits a fallacy of overgeneralization — those studies specifically examined oral contraceptives and levonorgestrel IUDs in aggregate, yet Source 2 and Source 5 demonstrate that risk is heterogeneous across hormonal contraceptive types, with specific agents like etonogestrel vaginal ring, medroxyprogesterone, and Mirena® showing statistically significant elevated odds ratios, meaning a null finding for "hormonal contraception broadly" does not negate elevated risk for specific formulations the claim encompasses. Furthermore, you dismiss Source 9 (MedlinePlus Medical Encyclopedia) — a highly authoritative NIH-affiliated reference — which explicitly lists levonorgestrel-containing birth control pills as medicines that increase IIH risk, and you cannot simply wave away an established clinical reference by pointing to studies that examine different contraceptive groupings without directly refuting that specific pharmacological evidence.